Contents
Premium Noble Kava
Entdecken Sie zertifizierte Qualität und Reinheit bei unserem offiziellen Partner.
Zu Kava-mode.comBrief & Concise
After comprehensive analyses by WHO, EMA, and independent researchers, the following is concluded:
- ●Traditionally prepared Kava from Noble varieties is safe when used properly
- ●Severe liver damage is extremely rare (estimated incidence: 1:60,000 to 1:1,000,000)
- ●Most case reports exhibited significant quality deficiencies in causality assessment
- ●The EU ban of 2002 was deemed disproportionate by German courts
The Ban of 2002
In 2002, Kava was removed from the market in Germany and many other European countries. The Federal Institute for Drugs and Medical Devices (BfArM) revoked the approvals for Kava-containing medicines after reports of severe liver damage were received. This decision had far-reaching consequences for the global Kava market and the Pacific producing countries.
Chronology of Events
For detailed information on the current legal status in various countries, see Legal Status & Legality.
What Really Happened: A Critical Analysis
The original case reports that led to the ban were intensively studied in the following years. Significant methodological deficiencies were revealed:
Problems with the Case Reports
- •Incomplete documentation in over 50% of cases
- •No standardized causality assessment (RUCAM)
- •Comedication with hepatotoxic substances ignored
- •Alcohol consumption often undocumented
- •Product quality and plant parts unclear
Later Findings
- •Many products contained above-ground plant parts
- •Acetonic extracts showed higher risk than aqueous ones
- •Tudei Kava was sometimes sold as Noble
- •Mold contamination detected in some products
- •Genetic polymorphisms identified as a risk factor
Rehabilitation by the Courts
After years of legal disputes, German courts reached a clear conclusion. The Administrative Court of Cologne and later the Higher Administrative Court of Münster found that the ban was disproportionate and that the authorities had not correctly assessed the scientific evidence.
"The causality assumed by BfArM between the intake of Kava-containing medicines and the occurred liver damage is not sufficiently substantiated. The risk-benefit assessment was conducted incorrectly."
The Scientific Evidence
After the ban, several comprehensive scientific evaluations were conducted, painting a more nuanced picture of Kava safety.
WHO Assessment 2007
The World Health Organization (WHO) conducted a comprehensive analysis of all available case reports in 2007. The results were revealing:
WHO Analysis of 93 Case Reports
The WHO found that acetonic and ethanolic extracts posed a higher risk than synthetic Kavalactones, indicating non-Kavalactone components as a possible cause.
EMA Assessment 2017
The European Medicines Agency (EMA) published a 103-page assessment report in 2017 summarizing all available data:
- Clinical Studies: No significant hepatotoxicity in controlled studies
- Side Effects: Only mild, reversible transaminase elevations in a few subjects
- Risk Factors: Organic extracts, alcohol, pre-existing liver disease, genetic polymorphisms
Evidence from Clinical Studies
A particularly important point: In controlled clinical studies with standardized Kava preparations, no severe liver damage was observed. A systematic review by Smith & Leiras (2018) analyzed 11 randomized studies and found no evidence of hepatotoxicity.
Summary of Study Findings
| Study | Participants | Duration | Liver Damage |
|---|---|---|---|
| Sarris et al. (2013) | 75 | 6 weeks | None |
| Boerner et al. (2003) | 129 | 8 weeks | None* |
| Lehrl (2004) | 40 | 4 weeks | None |
| Cochrane Review (2003) | 645 (7 studies) | 1-24 weeks | None |
*Mild transaminase elevations in 2 subjects, one had already elevated baseline values
Identified Risk Factors
Scientific research has identified several factors that may increase the risk of hepatic side effects. Understanding these factors allows for safe use.
Extract Types: Aqueous vs. Organic
A central finding of the WHO analysis was the difference between various extraction methods:
Aqueous Extracts (traditional)
- • Traditional preparation method
- • Primarily extracts Kavalactones
- • Contains protective glutathione
- • No documented hepatotoxicity in Pacific populations
- • Classified as safe by FAO/WHO
Organic Extracts (acetonic/ethanolic)
- • Industrial extraction method
- • Higher Kavalactone concentration
- • Also extracts flavokavins
- • Glutathione is not extracted
- • Higher risk in WHO analysis
Plant Parts: Root vs. Above-Ground Parts
The use of different plant parts has significant implications for safety:
Pipermethystin Content by Plant Part
| Plant Part | Pipermethystin | Safety |
|---|---|---|
| Root/Rhizome | Not detectable | Safe |
| Stem Sheaths | Up to 0.85% | Problematic |
| Leaves | Approx. 0.2% | Toxic |
Pipermethystin is an alkaloid that is highly cytotoxic in vitro and disrupts mitochondrial function (Nerurkar et al., 2004). It is found exclusively in above-ground plant parts.
Genetic Factors: CYP2D6 Polymorphisms
Kavalactones are primarily metabolized through the cytochrome P450 enzyme system, particularly via CYP2D6. Genetic variants of this enzyme can significantly affect the metabolism rate:
- Poor Metabolizers (PM): About 5-10% of Europeans have reduced CYP2D6 activity, which can lead to higher Kavalactone levels
- Idiosyncratic Reactions: Some cases may be due to immune-mediated mechanisms
Comedication & Alcohol
The WHO identified the following comedications as particularly problematic:
- • Alcohol (synergistic hepatotoxicity)
- • Paracetamol/Acetaminophen (hepatotoxic)
- • Benzodiazepines (CYP interaction)
- • Antipsychotics (CYP interaction)
- • Statins (hepatotoxic potential)
Possible Mechanisms of Hepatotoxicity
The exact mechanisms by which Kava can cause liver damage in rare cases are not yet fully understood. Several hypotheses are being discussed:
1. Quinone Metabolites
Kavain and Dihydrokavain can be oxidized to reactive quinone metabolites that can react with cellular proteins and cause oxidative stress (Johnson et al., 2003). Glutathione can neutralize these metabolites – a possible reason why aqueous extracts (which contain glutathione) are safer.
2. Flavokavins
Flavokavin B shows in vitro cytotoxicity and can induce apoptosis in hepatocytes. Organic extracts contain higher concentrations of flavokavins than aqueous preparations.
3. Pipermethystin
This alkaloid from above-ground plant parts is highly hepatotoxic and disrupts mitochondrial function. It is not present in the root but can enter products through contamination.
4. Idiosyncratic Reactions
Some cases may be due to immune-mediated, idiosyncratic reactions that occur independently of dose and are genetically determined.
Practical Recommendations for Safe Consumption
Based on the scientific evidence, clear recommendations for safe Kava consumption can be derived:
Checklist for Safe Kava Consumption
- Use only Noble Kava
Pay attention to the variety designation and buy from trusted sources
- Use only root/rhizome
No products with leaves or stem sheaths
- Prefer traditional aqueous preparation
Kneading or blender method with water
- Do not consume alcohol
At least 24 hours before and after Kava consumption
- Be aware of medication interactions
See Interactions
- Avoid in liver diseases
See Contraindications
- Maintain moderate dosing
No more than 250mg Kavalactones per day with regular consumption
Continue in the Safety Chapter
Based on studies by
This wiki is a curated resource that synthesizes research from peer-reviewed studies and expert researchers. It is not written by the researchers listed above, but rather based on their published work.
Scientific Sources
The information on this page is based on the following scientific studies and publications:
In Vitro Toxicity of Kava Alkaloid, Pipermethystine, in HepG2 Cells Compared to Kavalactones
Nerurkar P.V., Dragull K., Tang C.S. (2004) – Toxicological Sciences
View studyNekrotisierende Hepatitis nach Einnahme pflanzlicher Heilmittel
Strahl S., Ehret V., Dahm H.H., Maier K.P. (2008) – Deutsche Medizinische Wochenschrift
View studyFatal fulminant hepatic failure induced by a natural therapy containing kava
Gow P.J., Connelly N.J., Crowley P., Angus P.W., Hill R.L. (2003) – Medical Journal of Australia
View studyAcute Liver Failure After Administration of the Herbal Tranquilizer Kava-Kava (Piper methysticum)
Humberston C.L., Akhtar J., Krenzelok E.P. (2003) – Journal of Clinical Psychiatry
View studyContents
Premium Noble Kava
Entdecken Sie zertifizierte Qualität und Reinheit bei unserem offiziellen Partner.
Zu Kava-mode.com
common:ui.bookTitle
common:ui.bookDescription